Drug name - Cabometyx

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7579473 EXELIXIS INC c-Met modulators and methods of use
Aug, 2026

(3 years from now)

US11091439 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(7 years from now)

US8877776 EXELIXIS INC (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(8 years from now)

CN102388024A EXELIXIS INC Malate Salt Of N-(4-{[6,7-Bis (Methyloxy) Quinolin-4-Yl] Oxy} Phenyl-N'-(4-Fluorophenyl) Cyclopropane-1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Or Cancer
Sep, 2019

(3 years ago)

CN106083714A EXELIXIS INC N - (4 - {[6, 7-Bis - (Methyl) -4 - Yl] Oxy} Phenyl) -N '-(4) -1, 1 -- Dicarboxamide Malate And Its Crystal
May, 2022

(4 months ago)

CN106083714B EXELIXIS INC N --(4 - [6, 7 --(Methyl Oxy) Quinoline - -4--- Yl] Oxy} Phenyl) -N '--(4 - - Fluorophenyl) -1, 1-Dimethanamide Malate And Its Crystalline
May, 2022

(4 months ago)

EP2409704A3 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2210607B1 EXELIXIS INC N-[3-Fluoro-4-({6-(Methyloxy)-7-[(3-Morpholin-4-Ylpropyl)Oxy]Quinolin-4-Yl}Oxy)Phenyl]-N'-(4-Fluorophenyl)Cyclopropane-1,1-Dicarboxamide For The Treatment Of Cancer
Sep, 2024

(1 year, 11 months from now)

EP2392565B1 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP1673085B1 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2210607A1 EXELIXIS INC N-[3-Fluoro-4-({6-(Methyloxy)-7-[(3-Morpholin-4-Ylpropyl)Oxy]Quinolin-4-Yl}Oxy)Phenyl]-N'-(4-Fluorophenyl)Cyclopropane-1,1-Dicarboxamide For The Treatment Of Cancer
Sep, 2024

(1 year, 11 months from now)

EP1673085A4 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP3329918A3 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP3329918A2 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP1673085A2 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2392564A1 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2409704B1 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2392565A1 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2392564B1 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP3329918B1 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2409704A2 EXELIXIS INC C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2213661B1 EXELIXIS INC C-Met Modulators And Methods Of Use
Mar, 2029

(6 years from now)

EP2213661A1 EXELIXIS INC C-Met Modulators And Methods Of Use
Mar, 2029

(6 years from now)

EP2387563A1 EXELIXIS INC Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

EP2387563B2 EXELIXIS INC Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

EP2387563B1 EXELIXIS INC Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284 EXELIXIS INC C-met modulators and method of use Sep, 2024

(1 year, 11 months from now)

US11091440 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer Jan, 2030

(7 years from now)

US11098015 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer Jan, 2030

(7 years from now)

US10039757 EXELIXIS INC C-Met modulator pharmaceutical compositions Jul, 2031

(8 years from now)

US10034873 EXELIXIS INC C-met modulator pharmaceutical compositions Jul, 2031

(8 years from now)

US9724342 EXELIXIS INC C-met modulator pharmaceutical compositions Jul, 2033

(10 years from now)

US11141413 EXELIXIS INC Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate Apr, 2037

(14 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: Treatment of renal cell carcinoma; treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; treatment of advanced renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; treatment of renal cell carcinoma; treatment of advanced renal cell carcinoma; treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy; Treatment of advanced renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription
EQ 60MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.